Related Experiment Videos
Exploring Targets for Heart Failure Using Mendelian Randomization, Colocalization, Summary Data-based Mendelian
1Department of Cardiovascular Medicine, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University.
Insights
This study identified eight novel therapeutic targets for heart failure (HF) using Mendelian randomization. These targets, including genes like CYP11A1 and APOM, offer new avenues for drug development to improve patient outcomes.
Area of Science:
- Cardiovascular Genetics
- Pharmacogenomics
- Systems Biology
Background:
- Heart failure (HF) is a widespread cardiovascular condition with a substantial impact on quality of life.
- Current HF treatments are insufficient, highlighting the need for novel therapeutic strategies.
- Identifying causal genetic factors is crucial for developing effective HF interventions.
Purpose of the Study:
- To investigate the causal relationships between druggable genes and heart failure (HF).
- To identify novel genetic targets for potential HF therapies.
- To explore drug candidates for these identified targets.
Main Methods:
- Mendelian randomization (MR) was employed to assess gene-HF causality.
- Colocalization and summary data-based Mendelian randomization (SMR) analyses were used for validation.
- Gene enrichment (GO, KEGG) and protein-protein interaction (PPI) network analyses were performed.
Main Results:
- Eight potential therapeutic targets for HF were identified: four risk factors (CYP11A1, GALT, KCNH2, METRN) and four protective factors (APOM, CHD4, IL11RA, LPAR5).
- These genes are significantly involved in metabolic regulation and cardiac electrophysiological processes.
- Potential drugs (e.g., mitotane) targeting these genes were identified, with mitotane showing association with CYP11A1 and KCNH2.
Conclusions:
- This study provides a robust list of potential genetic targets for heart failure.
- The identified targets and drug candidates offer promising avenues for developing more successful HF treatments.
- Further research into these targets could lead to improved clinical outcomes for HF patients.
Abstract:
Heart failure (HF) is a prevalent cardiovascular disease that significantly impairs quality of life in its advanced stages. Despite a variety of current treatment strategies, the disease burden of HF remains significant. Therefore, exploring novel therapeutic targets is urgently needed. This study utilized Mendelian randomization (MR) to evaluate the causal relationships between druggable genes and HF. Colocalization analysis and summary data-based Mendelian randomization (SMR) were conducted to further validate the relationship between them. Finally, 8 potential therapeutic targets for HF were identified, including 4 risk factors (CYP11A1, GALT, KCNH2, and METRN) and 4 protective factors (APOM, CHD4, IL11RA, and LPAR5). The GO enrichment, KEGG enrichment, and protein-protein interaction (PPI) network analysis indicated that these genes were primarily involved in metabolic regulation and cardiac electrophysiological processes. Moreover, potential drugs targeting these targets were identified using drug prediction and molecular docking, including mitotane, Adehl, Benzofurans, 1,3-Di-o-tolylguanidine, 96-69-5, and bromoenol lactone. Furthermore, PCR results also demonstrated that mitotane might be associated with CYP11A1 and KCNH2. Drugs designed based on these potential therapeutic targets may offer higher success rates and improve clinical outcomes.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...